{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:18:18Z","timestamp":1792167498369,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Dongcheng District Outstanding Talent Nurturing Program","award":["2022-dchrcpyzz-69"],"award-info":[{"award-number":["2022-dchrcpyzz-69"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-021"],"award-info":[{"award-number":["2022-PUMCH-A-021"]}]},{"name":"Research and Translation Application of Beijing Clinical Diagnostic Technologies Funds from Beijing Municipal Commission of Science and Technology","award":["Z211100002921016"],"award-info":[{"award-number":["Z211100002921016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00277-024-05783-z","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T12:52:52Z","timestamp":1714567972000},"page":"4223-4230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sirolimus is effective for refractory\/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-7153","authenticated-orcid":false,"given":"Yan-ting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7249-2855","authenticated-orcid":false,"given":"Yu-han","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-9700","authenticated-orcid":false,"given":"Hao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7776-3642","authenticated-orcid":false,"given":"Miao-yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-6300","authenticated-orcid":false,"given":"Ming-hui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-0694","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-9625","authenticated-orcid":false,"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"issue":"12","key":"5783_CR1","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","volume":"129","author":"DC Fajgenbaum","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A et al (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood 129(12):1646\u20131657. https:\/\/doi.org\/10.1182\/blood-2016-10-746933","journal-title":"Blood"},{"issue":"2","key":"5783_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24242","volume":"91","author":"N Iwaki","year":"2016","unstructured":"Iwaki N, Fajgenbaum DC, Nabel CS et al (2016) Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91(2):220\u2013226. https:\/\/doi.org\/10.1002\/ajh.24242","journal-title":"Am J Hematol"},{"issue":"16","key":"5783_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","volume":"135","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC (2020) Overview of Castleman disease. Blood 135(16):1353\u20131364. https:\/\/doi.org\/10.1182\/blood.2019000931","journal-title":"Blood"},{"issue":"20","key":"5783_CR4","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A et al (2018) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132(20):2115\u20132124. https:\/\/doi.org\/10.1182\/blood-2018-07-862334","journal-title":"Blood"},{"issue":"9","key":"5783_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/s1470-2045(14)70319-5","volume":"15","author":"F van Rhee","year":"2014","unstructured":"van Rhee F, Wong RS, Munshi N et al (2014) Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15(9):966\u2013974. https:\/\/doi.org\/10.1016\/s1470-2045(14)70319-5","journal-title":"Lancet Oncol"},{"issue":"3 Suppl","key":"5783_CR6","doi-asserted-by":"publisher","first-page":"7s","DOI":"10.1016\/s0041-1345(03)00211-2","volume":"35","author":"Sehgal","year":"2003","unstructured":"Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transpl Proc 35(3 Suppl):7s\u201314s. https:\/\/doi.org\/10.1016\/s0041-1345(03)00211-2","journal-title":"Transpl Proc"},{"issue":"11","key":"5783_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nrd3531","volume":"10","author":"D Benjamin","year":"2011","unstructured":"Benjamin D, Colombi M, Moroni C et al (2011) Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10(11):868\u2013880. https:\/\/doi.org\/10.1038\/nrd3531","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"5783_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/14656566.6.3.479","volume":"6","author":"A Mota","year":"2005","unstructured":"Mota A (2005) Sirolimus: a new option in transplantation. Expert Opin Pharmacother 6(3):479\u2013487. https:\/\/doi.org\/10.1517\/14656566.6.3.479","journal-title":"Expert Opin Pharmacother"},{"issue":"17","key":"5783_CR9","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J et al (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364(17):1595\u20131606. https:\/\/doi.org\/10.1056\/NEJMoa1100391","journal-title":"N Engl J Med"},{"issue":"5","key":"5783_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.semarthrit.2020.07.006","volume":"50","author":"L Ji","year":"2020","unstructured":"Ji L, Xie W, Zhang Z (2020) Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum 50(5):1073\u20131080. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.07.006","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"5783_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2141.2009.07595.x","volume":"145","author":"DT Teachey","year":"2009","unstructured":"Teachey DT, Greiner R, Seif A et al (2009) Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 145(1):101\u2013106. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07595.x","journal-title":"Br J Haematol"},{"issue":"7","key":"5783_CR12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ajh.25123","volume":"93","author":"SK Pierson","year":"2018","unstructured":"Pierson SK, Stonestrom AJ, Shilling D et al (2018) Plasma proteomics identifies a \u2018chemokine storm\u2019 in idiopathic multicentric Castleman disease. Am J Hematol 93(7):902\u2013912. https:\/\/doi.org\/10.1002\/ajh.25123","journal-title":"Am J Hematol"},{"issue":"10","key":"5783_CR13","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1172\/jci126091","volume":"129","author":"DC Fajgenbaum","year":"2019","unstructured":"Fajgenbaum DC, Langan RA, Japp AS et al (2019) Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 129(10):4451\u20134463. https:\/\/doi.org\/10.1172\/jci126091","journal-title":"J Clin Invest"},{"issue":"19","key":"5783_CR14","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1182\/blood.2019002792","volume":"135","author":"DJ Arenas","year":"2020","unstructured":"Arenas DJ, Floess K, Kobrin D et al (2020) Increased mTOR activation in idiopathic multicentric Castleman disease. Blood 135(19):1673\u20131684. https:\/\/doi.org\/10.1182\/blood.2019002792","journal-title":"Blood"},{"key":"5783_CR15","doi-asserted-by":"publisher","first-page":"108887","DOI":"10.1016\/j.clim.2021.108887","volume":"233","author":"R Sumiyoshi","year":"2021","unstructured":"Sumiyoshi R, Koga T, Furukawa K et al (2021) A case of tocilizumab-refractory idiopathic multicentric Castleman\u2019s disease successfully treated with sirolimus. Clin Immunol 233:108887. https:\/\/doi.org\/10.1016\/j.clim.2021.108887","journal-title":"Clin Immunol"},{"issue":"2","key":"5783_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ajh.26783","volume":"98","author":"E Bayram","year":"2023","unstructured":"Bayram E, Pehlivan UA, Fajgenbaum DC et al (2023) Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy. Am J Hematol 98(2):361\u2013364. https:\/\/doi.org\/10.1002\/ajh.26783","journal-title":"Am J Hematol"},{"key":"5783_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19334","author":"YH Gao","year":"2024","unstructured":"Gao YH, Liu YT, Zhang MY et al (2024) Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.19334","journal-title":"Br J Haematol"},{"key":"5783_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.exphem.2020.08.001","volume":"89","author":"H Li","year":"2020","unstructured":"Li H, Ji J, Du Y et al (2020) Sirolimus is effective for primary relapsed\/refractory autoimmune cytopenia: a multicenter study. Exp Hematol 89:87\u201395. https:\/\/doi.org\/10.1016\/j.exphem.2020.08.001","journal-title":"Exp Hematol"},{"issue":"10126","key":"5783_CR19","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/s0140-6736(18)30485-9","volume":"391","author":"ZW Lai","year":"2018","unstructured":"Lai ZW, Kelly R, Winans T et al (2018) Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial. Lancet 391(10126):1186\u20131196. https:\/\/doi.org\/10.1016\/s0140-6736(18)30485-9","journal-title":"Lancet"},{"issue":"8","key":"5783_CR20","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.transproceed.2012.07.003","volume":"44","author":"CH Reigada","year":"2012","unstructured":"Reigada CH, de Ataide EC, de Ara\u00fajo FR et al (2012) Sirolimus as rescue therapy after liver transplantation. Transpl Proc 44(8):2434\u20132437. https:\/\/doi.org\/10.1016\/j.transproceed.2012.07.003","journal-title":"Transpl Proc"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05783-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05783-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05783-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:03:55Z","timestamp":1729933435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05783-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5783"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05783-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single-center retrospective study was approved by the medical ethics committee of Peking Union Medical College Hospital. All procedures performed in studies were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}